Profile data is unavailable for this security.
About the company
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
- Revenue in USD (TTM)82.56m
- Net income in USD-348.62m
- Incorporated2014
- Employees673.00
- LocationImmunitybio Inc3530 JOHN HOPKINS COURTSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 633-0300
- Fax+1 (302) 674-5266
- Websitehttps://immunitybio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | 598.70m | -14.06m | 4.49bn | 499.00 | -- | 19.14 | -- | 7.50 | -0.0458 | -0.0458 | 1.94 | 0.7469 | 0.7234 | 0.4175 | 5.65 | 1,199,808.00 | -1.70 | -23.63 | -2.17 | -28.66 | 89.77 | 89.34 | -2.35 | -53.29 | 2.09 | 0.8067 | 0.6298 | -- | 32.29 | 23.72 | 62.99 | -- | -29.23 | -- |
| Crinetics Pharmaceuticals Inc | 1.54m | -423.10m | 4.52bn | 437.00 | -- | 4.20 | -- | 2,943.19 | -4.53 | -4.53 | 0.0165 | 11.34 | 0.0014 | -- | 0.2622 | 3,512.59 | -39.66 | -36.96 | -42.19 | -39.20 | -- | -- | -27,563.32 | -7,785.98 | -- | -- | 0.00 | -- | -74.11 | -2.73 | -39.10 | -- | 50.86 | -- |
| Celcuity Inc | 0.00 | -162.72m | 4.82bn | 87.00 | -- | 38.54 | -- | -- | -3.67 | -3.67 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -43.45 | -42.61 | -47.58 | -45.75 | -- | -- | -- | -- | -- | -48.30 | 0.7325 | -- | -- | -- | -75.26 | -- | -8.05 | -- |
| Scholar Rock Holding Corp | 0.00 | -353.43m | 4.86bn | 196.00 | -- | 19.28 | -- | -- | -3.15 | -3.15 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -119.63 | -45.06 | -144.40 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.2891 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Protagonist Therapeutics Inc | 209.22m | 45.91m | 5.24bn | 128.00 | 132.86 | 8.12 | 110.75 | 25.06 | 0.6313 | 0.6313 | 3.26 | 10.34 | 0.3205 | -- | 52.34 | 1,660,452.00 | 7.03 | -7.11 | 7.55 | -7.93 | -- | -- | 21.94 | -21.29 | -- | -- | 0.00 | -- | 624.06 | 351.71 | 448.54 | -- | 6.98 | -- |
| Immunovant Inc | 0.00 | -464.20m | 5.43bn | 362.00 | -- | 5.50 | -- | -- | -2.68 | -2.68 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -63.01 | -47.00 | -69.35 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -210.69m | 5.43bn | 218.00 | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -23.87 | -- | -25.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -36.72 | -- | -- | -- |
| Alkermes Plc | 1.52bn | 338.06m | 5.73bn | 1.80k | 17.20 | 3.31 | 15.57 | 3.77 | 2.02 | 2.02 | 9.06 | 10.50 | 0.6784 | 1.11 | 4.20 | 845,187.80 | 15.08 | 6.99 | 19.01 | 9.14 | 86.04 | 83.31 | 22.22 | 10.68 | 3.27 | -- | 0.00 | 0.00 | -6.36 | 5.87 | -28.32 | -- | -18.11 | -- |
| Kymera Therapeutics Inc | 43.73m | -295.12m | 6.34bn | 225.00 | -- | 6.03 | -- | 145.03 | -3.59 | -3.59 | 0.5332 | 13.19 | 0.0409 | -- | 66.41 | 232,627.70 | -27.62 | -23.82 | -29.53 | -27.88 | -- | -- | -674.81 | -240.35 | -- | -- | 0.0039 | -- | -40.11 | 74.20 | -52.32 | -- | 89.02 | -- |
| Immunitybio Inc | 82.56m | -348.62m | 6.46bn | 673.00 | -- | -- | -- | 78.27 | -0.4079 | -0.4079 | 0.0965 | -0.5323 | 0.1869 | 0.0857 | 4.56 | 121,404.40 | -78.93 | -109.27 | -91.33 | -251.12 | 90.40 | -- | -422.38 | -11,599.51 | 5.65 | -2.20 | 2.77 | -- | 2,270.58 | 46.27 | 29.09 | -- | 9.95 | -- |
| Cogent Biosciences Inc | 0.00 | -214.77m | 6.62bn | 205.00 | -- | 27.15 | -- | -- | -1.77 | -1.77 | 0.00 | 2.16 | 0.00 | -- | -- | 0.00 | -72.69 | -57.20 | -84.75 | -63.62 | -- | -- | -- | -9,345.59 | -- | -- | 0.1276 | -- | -- | -- | -30.01 | -- | 76.98 | -- |
| Belite Bio Inc (ADR) | 0.00 | -49.38m | 6.64bn | 25.00 | -- | 38.61 | -- | -- | -1.55 | -1.55 | 0.00 | 4.58 | 0.00 | -- | -- | 0.00 | -36.85 | -- | -36.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.26 | -- | -- | -- |
| Vaxcyte Inc | 0.00 | -657.20m | 7.75bn | 414.00 | -- | 2.47 | -- | -- | -4.84 | -4.84 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -19.53 | -26.00 | -20.51 | -27.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.33 | -- | 151.05 | -- |
| Nuvalent Inc | 0.00 | -381.44m | 7.88bn | 218.00 | -- | 8.73 | -- | -- | -5.32 | -5.32 | 0.00 | 11.70 | 0.00 | -- | -- | 0.00 | -35.18 | -25.32 | -37.61 | -26.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -106.59 | -- | -- | -- |
| Cytokinetics, Inc. | 87.21m | -751.94m | 7.93bn | 498.00 | -- | -- | -- | 90.92 | -6.31 | -6.31 | 0.7328 | -4.27 | 0.0607 | -- | 85.00 | 175,122.50 | -52.35 | -45.50 | -57.39 | -50.38 | -- | -- | -862.21 | -748.37 | -- | -14.45 | 1.96 | -- | 145.34 | -7.22 | -12.03 | -- | 8.32 | -- |
Data as of Feb 11 2026. Currency figures normalised to Immunitybio Inc's reporting currency: US Dollar USD
10.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 30.30m | 3.08% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 17.16m | 1.74% |
| Jane Street Capital LLCas of 30 Sep 2025 | 12.84m | 1.30% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 11.32m | 1.15% |
| Geode Capital Management LLCas of 30 Sep 2025 | 6.89m | 0.70% |
| Heights Capital Management, Inc.as of 30 Sep 2025 | 6.57m | 0.67% |
| Woodline Partners LPas of 30 Sep 2025 | 5.30m | 0.54% |
| AlphaCore Capital LLCas of 31 Dec 2025 | 3.00m | 0.31% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 2.79m | 0.28% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 2.64m | 0.27% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
